See updated messages from the NIDA HRP scientific leadership team.
Funding Opportunities of Note
- High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) RFA-DA-22-040
- NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional) PAR-20-221
- Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional) PAR-20-224
- AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional) PAS-21-270
Basic Research
- NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional) RFA-DA-23-028
- NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional) RFA-DA-23-029
- Notice of Intent to Publish a Funding Opportunity Announcement for Targeting Inflammasomes in Substance Abuse and HIV(R01 Clinical Trial Not Allowed). NOT-DA-22-070
- Investigating Transposable Elements and Mobile DNA as Targets of Integration for Establishing HIV Reservoirs in the Brain (R61/R33 - Clinical Trial Optional) RFA-DA-23-003
- Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional) PAR-21-310
- Imaging - Science Track Award for Research Transition (I/START) (R03 Basic Experimental Studies with Humans Required) PAR-21-309
- Notice of Special Interest (NOSI): Transcriptomic, epigenomic, regulatory RNA or functional genomic research in Substance Use Disorders NOT-DA-20-031
- Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) PAR-19-282
- Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R01- Clinical Trial Not Allowed) PAR-20-147
- Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R21- Clinical Trial Not Allowed) PAR-20-148
- Notice of Special Interest (NOSI): Exploring the Roles of Biomolecular Condensates (BMCs) in Substance Use Disorder and/or HIV-related processes. NOT-DA-20-018
- Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional) PAR-21-208
- Notice of Special Interest (NOSI): Identification of Biomarkers of HIV Pathogenesis and Substance Use Disorder Comorbidity. NOT-DA-21-014
- Notice of Special Interest (NOSI): Advancing Research on SUD through Computational Neuroscience. NOT-DA-20-022
- Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience. NOT-DA-21-030
Applied Research
- NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01 Clinical Trial Optional) RFA-DA-23-023
- NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R34 Clinical Trial Optional) RFA-DA-23-024
- Stimulants and HIV: Addressing Contemporary and Recurring Epidemics (R61/R33 - Clinical Trial Required). RFA-DA-23-008
- Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional). PAR-22-182
- Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional). PAR-22-183
- Pathogenic Mechanisms influencing Blood Brain Barrier function in HIVand Substance Use Disorders (R01 Clinical Trial Optional). RFA-DA-23-012
- Notice of NIDA Participation in NOT-MH-21-105, "Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure"
- Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R01 - Clinical Trial Required) RFA-DA-23-006
- Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R34 - Clinical Trial Required) RFA-DA-23-007
- Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) PAR-20-238
- Notice of Special Interest (NOSI): The HIV-HCV-Substance Use Disorder Syndemic: Therapeutic Approaches. NOT-DA-20-032
- Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R34 Clinical Trial Optional) PAR-21-023
- Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Use and Addiction Scientists (R25 Clinical Trials Not Allowed) PAR-20-236
- Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional) PA-21-110
- Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional) PA-21-180
- Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and Substance Use Disorders. NOT-DA-21-019
- Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) PAR-22-027
Opportunities that Could be Basic or Applied
- Notice of Special Interest (NOSI): Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A jump into Precision Medicine – NOT-DA-24-001
- Mechanisms and Targets at the Intersection of HIV and Substance Use (R21 Clinical Trials Not Allowed) RFA-DA-24-014
- Mechanisms and Targets at the Intersection of HIV and Substance Use (R01 Clinical Trials Not Allowed) RFA-DA-24-013
- Notice of Special Interest (NOSI): Research to Address Ending the HIV Epidemic Initiative Goals Relevant to Substance Using Populations At-Risk for or Living with HIV, NOT-DA-23-013
- Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed) RFA-DA-24-002
- Notice of Special Interest (NOSI): Chemsex and HIV: prevalence, medical/psychosocial consequences, and treatment, NOT-DA-24-002
- Targeting Inflammasomes in Substance Abuse and HIV (R21 Clinical Trial Not Allowed) RFA-DA-24-004
- Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed) RFA-DA-24-003
- NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R01 Clinical Trial Optional) RFA-DA-23-061
- NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R34 Clinical Trial Optional) RFA-DA-23-062
- NIDA Program Project Grant Applications (P01 Clinical Trial Optional). PAR-22-201
- NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional) PAR-20-221
- Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional) PAR-20-224
- Substance Use/Substance Use Disorder Dissertation Research Award (R36 - Clinical Trials Optional) PA-20-208
- Notice of Special Interest (NOSI): Research Training and Career Development Awards to Support Individuals Pursuing Research Focused on Developing Treatments for Substance Use Disorders and the Associated Medical Consequences of these Disorders. NOT-DA-20-037
- NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) PAR-20-249
- Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders. NOT-DA-21-018
- Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19. NOT-DA-21-017
- Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning. NOT-DA-21-007
- AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional) PAS-21-270
- HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional) RFA-DA-22-040